Crispr Therapeutics shares tumble after significant earnings miss
Tyler Brian S., the Chief Executive Officer of McKesson Corporation (NYSE:MCK), a healthcare services giant with a market capitalization of $80.6 billion and annual revenue exceeding $344 billion, recently sold 8,961 shares of the company’s common stock. The transaction, which took place on February 28, 2025, was executed at a price of $624 per share, amounting to a total of approximately $5.6 million. This sale was conducted under a previously adopted trading plan, compliant with Rule 10b5-1(c). According to InvestingPro data, MCK stock is currently trading near its 52-week high, with analysis suggesting the stock may be undervalued based on its Fair Value assessment. Following the transaction, Tyler retains direct ownership of 51,703 shares of McKesson stock. Additionally, he holds an indirect ownership of 199.8208 shares through the McKesson Corporation 401(k) Retirement Savings Plan. InvestingPro analysis reveals the company maintains a "GREAT" financial health score, with 12 additional exclusive insights available to subscribers, including detailed valuation metrics and growth indicators.
In other recent news, McKesson Corporation reported third-quarter earnings and revenue that fell short of analyst expectations, with adjusted earnings per share at $8.03, missing the consensus of $8.27. Despite this, revenue grew 18% year-over-year to $95.29 billion, though it was below the forecasted $95.77 billion. In light of these results, McKesson raised its full-year adjusted EPS guidance to a range of $32.55 to $32.95. The U.S. Pharmaceutical (TADAWUL:2070) segment, McKesson’s largest, saw a 19% revenue increase, driven by increased prescription volumes and growth in the oncology platform.
Additionally, McKesson announced plans to acquire a controlling interest in PRISM Vision Holdings LLC for $850 million and Florida Cancer Specialists & Research Institute for $2.5 billion, aligning with its strategy to expand in higher-margin specialty services. S&P Global Ratings revised its outlook on McKesson to positive from stable, affirming its ’BBB+’ rating, based on anticipated growth in the U.S. pharmaceutical segment and prescription technology business. Citi analyst Daniel Grosslight raised the price target for McKesson shares to $685, maintaining a Buy rating, following a mixed financial performance where the pharmaceutical segment outperformed expectations. Despite challenges in the Med-Surg division, McKesson’s management is optimistic about a $100 million cost optimization strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.